Promising combo targets Hard-to-Treat childhood cancers

NCT ID NCT06607692

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 25 participants will receive the treatment every 8 weeks for up to four cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
177Lu-DOTATATE (Lutathera) and olaparib
What this could lead to
If successful, this combination could offer a new treatment option for children with certain hard-to-treat cancers that have come back after standard therapy.
What could go wrong
This is an early-phase trial with only 25 participants, so the benefits are uncertain. The combination may cause significant side effects, and it is not yet known if it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • HM Monteprincipe

    RECRUITING

    Boadilla del Monte, Madrid, 28660, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.